Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-322 vs Bevacizumab with FOLFIRI in Second-Line Metastatic Colorectal Cancer
NCT00851045Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2009
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of pegdinetanib in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Oct 2009; status: completed.
02
Drugs
pegdinetanib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00851045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851045.